comparative potency of formulations of mometasone furoate in terms of inhibition of ′pirhr′ in the forearm skin of normal human subjects measured with laser doppler velocimetry

Clicks: 179
ID: 257550
2005
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #112 of 318 articles by views in crystallization of organic compounds: an industrial perspective

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND AND AIMS: Topical glucocorticoid formulations are widely used for effective treatment and control of a variety of dermatoses. Mometasone furoate is a newer corticoid that has high potency but low systemic toxicity. Pharmaceutical factors are known to significantly influence potency and systemic absorption of topically applied glucocorticoids. We studied the potency of "Elocon", a topical formulation of mometasone furoate, compared with two other branded formulations of the same corticoid. METHODS: Corticoid potency was measured by employing a pharmacodynamic parameter of an inhibitory effect of the corticoid on post-ischemic-reactive-hyperemic-response (PIRHR) in human forearm skin under occlusive dressing. The PIRHR was expressed in terms of % increase in the skin blood flow (SBF) as measured with laser doppler velocimetry (LDV). RESULTS : All three active branded formulations of mometasone furoate produced significant inhibition of PIRHR. The AUC(0-2min) of PIRHR was ( Mean ± SEM ), Control = 213.52 ± 11.80, Placebo = 209.77 ± 19.31, Formulation A = 119.83 ± 13.71, Formulation C = 53.67 ± 4.85 and Formulation D = 111.46 ± 22.87. Formulation "C" exhibited significantly higher topical anti-inflammatory potency than formulations "A" or "D". CONCLUSIONS: Thus, branded formulations of the same glucocorticoid, mometasone furoate significantly differed in their topical anti-inflammatory potency. "Elocon" was significantly more potent than the two other branded formulations studied.
Reference Key
prabhakar2005indiancomparative Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kulhalli Prabhakar, Chevli Tejal, Karnik Rupal, Sheth Manish, Mulgaonkar Nitin
Are you one of these authors? Claim your profile
Journal crystallization of organic compounds: an industrial perspective
Year 2005
DOI
DOI not found
URL
http://www.ijdvl.com/article.asp?issn=0378-6323;year=2005;volume=71;issue=3;spage=170;epage=174;aulast=Kulhalli
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.